Virology

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, August 3, 2023

We plan to provide a further update on this clinical trial when we have additional meaningful patient data.

Key Points: 
  • We plan to provide a further update on this clinical trial when we have additional meaningful patient data.
  • Preliminary data from patients in the clinical trial are expected in the second half of 2023.
  • The Phase 1 clinical trial with AB-161 is on-going with single-ascending dose data expected in the second half of 2023.
  • We expect to nominate an nsp12 inhibitor clinical candidate and initiate IND-enabling studies in the second half of 2023.

Opteev Develops World's First Multiplex Biochip That Precisely Identifies COVID, Flu, RSV, and Respiratory Pathogens in Under 1 Minute

Retrieved on: 
Monday, July 31, 2023

The groundbreaking polymer-based biochip offers the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute.

Key Points: 
  • The groundbreaking polymer-based biochip offers the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute.
  • "With the development of our multiplex biochip, we are revolutionizing point-of-care diagnostics," said Dr. Mesfin Meshesha, Vice President of Virology & Diagnostics at Opteev Technologies.
  • As Opteev Technologies continues to push the boundaries of point-of-care diagnostics, the company welcomes potential collaborations and partnerships to further develop and commercialize its multiplex biochip.
  • For more information about Opteev Technologies and its groundbreaking multiplex biochip, please visit www.opteev.com .

Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships advance the next generation of leaders

Retrieved on: 
Tuesday, July 25, 2023

NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.

Key Points: 
  • NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.
  • The fellowships, the vision of Lady Mireille Gillings, are curated by an unprecedented group of international partners made up of the University of Cambridge, the University of North Carolina Gillings School of Global Public Health and Concordia University, Montreal.
  • "Future leaders in public health must have skills across what I call the 3Ms: management, money and medicine," said Lady Mireille Gillings, "The fellowships are designed to build business acumen on top of scientific experience, which is critical for the next generation of global scientists."
  • "The Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships are funded and supported by visionary leadership from Lady Mireille Gillings.

Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships advance the next generation of leaders

Retrieved on: 
Tuesday, July 25, 2023

NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.

Key Points: 
  • NEW YORK, and PARIS, July 25, 2023 /PRNewswire/ -- The Pasteur Foundation US and the Institut Pasteur are pleased to announce that the 2023 cohort of Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships have been conferred.
  • The fellowships, the vision of Lady Mireille Gillings, are curated by an unprecedented group of international partners made up of the University of Cambridge, the University of North Carolina Gillings School of Global Public Health and Concordia University, Montreal.
  • "Future leaders in public health must have skills across what I call the 3Ms: management, money and medicine," said Lady Mireille Gillings, "The fellowships are designed to build business acumen on top of scientific experience, which is critical for the next generation of global scientists."
  • "The Lady Mireille and Sir Dennis Gillings Global Public Health Fellowships are funded and supported by visionary leadership from Lady Mireille Gillings.

Introducing Anbio's Molecular RT-PCR Solution: Empowering Precision Diagnostics Across Diverse Clinical Applications

Retrieved on: 
Tuesday, July 25, 2023

Anbio molecular diagnostic test menu spans multiple clinical applications including healthcare-associated infections, critical infectious disease, sexual health, virology, pharmacogenomics, and oncology.

Key Points: 
  • Anbio molecular diagnostic test menu spans multiple clinical applications including healthcare-associated infections, critical infectious disease, sexual health, virology, pharmacogenomics, and oncology.
  • Anbio molecular diagnostic tests can be employed in institutions of any size, from small medical clinics to high-volume reference laboratories and hospitals, to access the speed and accuracy of molecular diagnostics.
  • Our approach to molecular diagnostics (MDx) simplifies the challenges associated with RT-PCR, catering to the requirements of both novice and experienced users in quantitative reverse transcriptase PCR (qRT-PCR).
  • To learn more about our RT-PCR solution and Anbio's range of innovative diagnostic solutions, please visit www.anbio.com .

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

Retrieved on: 
Thursday, July 20, 2023

WARMINSTER, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2023 financial results and corporate update for Thursday, August 3, 2023.

Key Points: 
  • WARMINSTER, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2023 financial results and corporate update for Thursday, August 3, 2023.
  • The schedule for the press release and conference call/webcast are as follows:
    To dial-in for the conference call by phone, please register using the following link: Registration Link .
  • A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com .
  • An archived webcast will be available on the Arbutus website after the event.

Central Component of Infection Revealed in People Living with HIV

Retrieved on: 
Thursday, July 13, 2023

QUÉBEC, July 13, 2023 /CNW/ - Professor Simona Stäger 's team has made a breakthrough in the study of the human immunodeficiency virus (HIV).

Key Points: 
  • QUÉBEC, July 13, 2023 /CNW/ - Professor Simona Stäger 's team has made a breakthrough in the study of the human immunodeficiency virus (HIV).
  • The researchers have identified the mechanism by which memory CD4+ T lymphocytes—cells that play a major role in our immune response—are predisposed to cell death in people living with HIV.
  • In most people living with HIV and undergoing antiretroviral treatment, residual inflammation persists despite some degree of viral control.
  • In 80% of people living with HIV and receiving treatment, this discovery could help preserve memory cells.

EQS-News: Peer-reviewed publication by Marinomed Biotech AG and Friedrich-Alexander-University Erlangen-Nürnberg reconfirms broad virus-blocking effectiveness of iota-carrageenan

Retrieved on: 
Thursday, July 13, 2023

Joint publication of virologists in the peer-reviewed journal Nutraceuticals demonstrates effectiveness of iota-carrageenan (Carragelose) against SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.5

Key Points: 
  • Joint publication of virologists in the peer-reviewed journal Nutraceuticals demonstrates effectiveness of iota-carrageenan (Carragelose) against SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.5
    Korneuburg, Austria, 13 July 2023 – Marinomed Biotech AG (VSE:MARI) and scientists from Friedrich-Alexander University Erlangen-Nürnberg and University Hospital Tuebingen published new data on the virus-blocking effectiveness of iota-carrageenan.
  • The authors investigated the virus-blocking properties of three different types of carrageenan (iota, kappa and lambda).
  • While all carrageenan types had a virus-blocking effect, iota-carrageenan showed superior inhibition of all tested viral subtypes.
  • This is confirmed by our newly published data that join a growing number of publications proving the virus-blocking effects of iota-carrageenan.

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

Retrieved on: 
Wednesday, July 12, 2023

“We are excited to welcome Dr. Rewolinski to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus.

Key Points: 
  • “We are excited to welcome Dr. Rewolinski to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus.
  • She currently serves as a board member for Lannett Company, Inc., and American Type Culture Collection (ATCC).
  • Dr. Rewolinski, commented, “This is an exciting time to join the Board of Arbutus.
  • I look forward to working with my fellow Board members to support Arbutus in its continued efforts to develop treatments for HBV and coronaviruses.”

Best Presentation Award at EASL Congress 2023: First-in-class Bispecific Antibodies Anti-HBs×CD3 and Anti-HBs×CD28 Showed Strong Preclinical Efficacy in HBV Cure

Retrieved on: 
Wednesday, July 12, 2023

A combination of anti-HBs×CD3 and anti-HBs×CD28 activated human lymphocytes in HBV-infected human liver chimeric mice and demonstrated potent in vivo antiviral efficacy.

Key Points: 
  • A combination of anti-HBs×CD3 and anti-HBs×CD28 activated human lymphocytes in HBV-infected human liver chimeric mice and demonstrated potent in vivo antiviral efficacy.
  • Levels of HBV pgRNA, HBV DNA, and cccDNA in the liver dropped significantly, consistent with the decrease of HBV serum parameters, indicating efficient clearance of infected hepatocytes.
  • One in three humans experiences an HBV infection during their lifetime, and almost 300 million people are chronically infected worldwide.
  • Approximately 25% of chronic HBV infections progress to liver cancer, and HBV contributes to an estimated 820,000 deaths annually.